EUVIMEDEUVIMED entdecken
Crossref

Partial nephrectomy for clinical T2b, T3a, and T3b renal mass: evaluating trifecta achievement and surgical outcomes

Giacomo Musso, Margaret F Meagher, Ryan Nasseri, Devin Patel, Sunil Patel, Luke Wang, Zachary Hamilton, Mai Dabbas, Giuseppe Garofano, Dhruv Puri, Cesare Saitta, Michael A Liss und 1 weitere

World Journal of Urology · 2026

DOI: 10.1007/s00345-026-06220-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, 2026. Verfasst von Giacomo Musso und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Via Olgettina 60, 20132, Milan, Italy. Hauptthemen laut MEDLINE: Nephrectomy, Kidney Neoplasms, Carcinoma, Renal Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Stephen Weissman Kidney Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the feasibility, and outcomes of partial nephrectomy (PN) for clinical T2b, T3a, and T3b renal mass in a high-volume tertiary care setting. METHODS: We retrospectively analyzed patients who underwent open or robotic-assisted PN between 2017 and 2024 at a single academic center. Patients had imperative indications for PN [solitary kidney, chronic kidney disease CKD, bilateral neoplasm]. Data on perioperative outcomes, renal function, oncologic endpoints, and Trifecta achievement [no major surgical complications according to Clavien-Dindo classification (CD ≥ 3), negative surgical margins, 80% of estimated new baseline estimated glomerular filtration rate (eGFR)] were collected. Multivariable Firth logistic regression (MLRA) assessed predictors of failure to achieve Trifecta. RESULTS: We analyzed 103 patients with (12 T2b/88 T3a/3 T3b) renal mass (median tumor size 6.0 cm/median R.E.N.A.L. score 10). Median ischemia time was 37.0 min (cold in 45.6%, warm in 44.7% and segmental/clampless in 9.7%). Median blood loss was 200 mL. Major post-operative complications occurred in 20.4% [urine leak (9.7%), fluid collection (6.7%), hematoma (2.9%)]. Intraoperative complication rate was 1.9% (2 enterotomies). Microscopic positive surgical margins were observed in 10.7%; mean ΔeGFR was - 14.6 ml/min/1.73m2. At median 38-month follow-up, 3-year overall, cancer-specific and recurrence-free survival rates were 92%, 94% and 75%, respectively. Trifecta was achieved in 43.7% patients. On MLRA, receipt of neoadjuvant therapy was associated with higher odds of failure to achieve Trifecta (OR 3.25, 95%CI 1.15-9.20; p = 0.03). CONCLUSION: PN for large and complex locally-advanced renal tumors is feasible with acceptable outcomes in carefully selected patients with imperative indication for nephron preservation. Further investigation is requisite to delineate role of PN in locally-advanced renal mass.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NephrectomyKidney NeoplasmsCarcinoma, Renal CellHumansRetrospective StudiesFemaleTreatment OutcomeMaleNeoplasm StagingMiddle AgedFeasibility StudiesAgedPostoperative ComplicationsMargins of ExcisionGlomerular Filtration Rate

Stichwörter der Autor:innen

Complex renal massLocally advancedPartial nephrectomyRenal cell carcinomaSurgical outcomesTrifecta

Autor:innen und Institutionen

  • IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), Via Olgettina 60, 20132, Milan, Italy.
  • University Vita-Salute San Raffaele, Via Olgettina, 58, Milan, 20132, Italy.
  • Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA, 92037, USA.
  • Department of Urology, RUSH-MD Anderson Cancer Center, 1725 West Harrison Street, Suite 970, Chicago, IL, 60612, USA.
  • Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA, 92037, USA. iderweesh@gmail.com.
  • Department of Urology, RUSH-MD Anderson Cancer Center, 1725 West Harrison Street, Suite 970, Chicago, IL, 60612, USA. iderweesh@gmail.com.

Förderung

  • Stephen Weissman Kidney Cancer Research Fund

Zitieren

APA

Musso, G., Meagher, M. F., Nasseri, R., Patel, D., Patel, S., Wang, L., Hamilton, Z., Dabbas, M., Garofano, G., Puri, D., Saitta, C., Liss, M. A., & Derweesh, I. H. (2026). Partial nephrectomy for clinical T2b, T3a, and T3b renal mass: evaluating trifecta achievement and surgical outcomes. World Journal of Urology. https://doi.org/10.1007/s00345-026-06220-8

Vancouver

Musso G, Meagher MF, Nasseri R, Patel D, Patel S, Wang L, et al. Partial nephrectomy for clinical T2b, T3a, and T3b renal mass: evaluating trifecta achievement and surgical outcomes. World Journal of Urology. 2026. doi:10.1007/s00345-026-06220-8

BibTeX
@article{Musso2026,
  author = {Musso, Giacomo and Meagher, Margaret F and Nasseri, Ryan and Patel, Devin and Patel, Sunil and Wang, Luke and Hamilton, Zachary and Dabbas, Mai and Garofano, Giuseppe and Puri, Dhruv and Saitta, Cesare and Liss, Michael A and Derweesh, Ithaar H},
  title = {Partial nephrectomy for clinical T2b, T3a, and T3b renal mass: evaluating trifecta achievement and surgical outcomes},
  journal = {World Journal of Urology},
  year = {2026},
  doi = {10.1007/s00345-026-06220-8}
}
Kostenlos starten →